Exelixis - Oncology Specialist with Strong Pipeline, Positive Phase III Clinical Study Data for Zanzalintinib Opens Billion-Dollar Revenue Potential!
Reading Time: 1 minute
Business Driver: The US company Exelixis (EXEL) specializes in the development of active ingredients and medications in the field of oncology. With Cabometyx, Exelixis has a blockbuster product in this high-margin segment, which has already been approved for various indications (e.g., renal cell carcinoma, hepatocellular carcinoma, medullary thyroid cancer), including advanced renal cell carcinoma (RCC), hepatocellular carcinoma (HCC), and medullary thyroid cancer (MTC). Cabometyx acts as a tyrosine kinase inhibitor and targets central growth and...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
